FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML
NCT ID: NCT00559221
Last Updated: 2008-10-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
37 participants
INTERVENTIONAL
2004-12-31
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
FLAG+IDA
Fludarabine, cytarabine, G-CSF
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FLAG+IDA
Fludarabine, cytarabine, G-CSF
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Early relapse, occurring after a first CR lasting less than 12 months.
* Patients with multiple relapses will be included.
* Written informed consent must be given.
* 15 and 60 years of age.
* 2 or less by ECOG performance scale.
Exclusion Criteria
* pregnant or lactating
15 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cooperative Study Group A for Hematology
NETWORK
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hawk Kim, professor
Role: PRINCIPAL_INVESTIGATOR
Ulsan Universtity Hospital, ROK
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asan Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yae-Eun, Jang
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Kim H, Lee JH, Joo YD, Bae SH, Lee JH, Kim DY, Lee WS, Ryoo HM, Jo JC, Choi Y, Lee KH; CoOperative Study Group A for Hematology (COSAH). A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60 yr with resistant acute myeloid leukemia: a comparison with intensive younger patients' trial. Eur J Haematol. 2016 Feb;96(2):188-97. doi: 10.1111/ejh.12568. Epub 2015 May 6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C-007A
Identifier Type: -
Identifier Source: org_study_id